| Aug 28 |
Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024
|
| Aug 14 |
Ascendis (ASND) Up on FDA Nod for Hormone Therapy Yorvipath
|
| Aug 14 |
Ascendis Pharma (ASND) Surges 8.7%: Is This an Indication of Further Gains?
|
| Aug 13 |
Ascendis Pharma: Yorvipath Approved, Launch Delayed, Many Other Updates Coming Up
|
| Aug 13 |
FDA approves Ascendis Pharma’s YORVIPATH for hypoparathyroidism
|
| Aug 12 |
Ascendis Pharma Zips Higher After FDA Approves Embattled Drug
|
| Aug 12 |
Ascendis Pharma stock jumps after FDA clears hypoparathyroidism therapy
|
| Aug 12 |
FDA approves Ascendis drug for rare endocrine condition
|
| Aug 12 |
FDA Approves YORVIPATH® (Palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in Adults
|
| Aug 9 |
$100 Invested In This Stock 10 Years Ago Would Be Worth $5,900 Today
|
